Cornerstone Therapeutics Receives Approval to Acquire Commercial Rights to the Antibiotic ... (es and projected costs; our management's...)

Cornerstone Therapeutics Receives Approval to Acquire Commercial Rights to the Antibiotic Factive(R)

Date:9/3/2009

es and projected costs; our management's prospects, plans and objectives; and any other statements about management's future expectations, beliefs, goals, plans or prospects constitute forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995.

Any statements that are not statements of historical fact (including, without limitation, statements containing the words "anticipate," "believe," "could," "estimate," "expect," "intend," "may," "plan," "should," "target," "will," "would" and similar expressions) should also be considered to be forward-looking statements.

There are a number of important factors that could cause our actual results or events to differ materially from those indicated by such forward-looking statements, including risks relating to the ability to complete and the expected timeline for completing the transaction with Oscient; our ability to develop and maintain the necessary sales, marketing, supply chain, distribution and manufacturing capabilities to commercialize our products, including difficulties relating to the manufacture of Zyflo CR((R)) tablets; the possibility that the Food and Drug Administration (the FDA) will take enforcement action against us or one or more of our marketed drugs that do not have FDA-approved marketing applications; patient, physician and third-party payor acceptance of our products as safe and effective therapeutic products; our heavy dependence on the commercial success of a relatively small number of currently marketed products; our ability to maintain regulatory approvals to market and sell our products that do have FDA-approved marketing applications; our ability to enter into additional strategic licensing, collaboration or co-promotion transactions on favorable terms, if at all; our ability to maintain compliance with NASDAQ listing requirements; adverse side effects experienced by patients taking our products; difficulties re
'/>"/>

SOURCE Cornerstone Therapeutics Inc.
Copyright©2009 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3 4 5
Related biology technology :

1. Cornerstone Therapeutics Announces Closing of Chiesi Transaction
2. Cornerstone Therapeutics Inc. Announces Record Date and Meeting Date for Special Meeting of Stockholders for Vote with Respect to Charter Amendments
3. Cornerstone Therapeutics to Present at BioCenturys 2009 Future Leaders in the Biotech Industry Conference
4. Cornerstone Therapeutics Reports Year Ended December 31, 2008 Financial Results
5. Cornerstone Therapeutics to Host Quarter and Year Ended December 31, 2008 Conference Call
6. Cornerstone Therapeutics Provides Update on Integration Activities and Issues 2008 Revenue Guidance
7. Cell Therapeutics, Inc. (CTI) to Present at Rodman & Renshaw Healthcare Conference
8. PTC Therapeutics Announces Celgene Exercised Option to Drug Discovery Collaboration
9. PTC Therapeutics Announces Drug Discovery Collaboration With Roche
10. United Therapeutics Corporation Announces Stock Split To Be Effected as a Stock Dividend
11. Oxygen Biotherapeutics, Inc. to Present at Investment Conferences in New York and Zurich

Post Your Comments:

Cornerstone Therapeutics Receives Approval to Acquire Commercial Rights to the Antibiotic ...(es and projected costs; our management's...)